Partner developments draw fresh attention to Ligand

Recent partnership updates, including Pelthos expanding its portfolio through an acquisition, regulatory progress for Ohtuvayre in China, and ongoing clinical work by Palvella and LeonaBio, have put Ligand Pharmaceuticals (LGND) back in focus for many investors.

Those partner headlines sit alongside a share price of $198.84 and a 1-year total shareholder return of 69.57%, with recent momentum reflected in a 30-day share price return of 4.59% and a 3-year total shareholder return of 173.70%. This suggests investors are reacting to both recent updates and the longer royalty driven story.

If you are looking beyond Ligand for ideas in the same space, this could be a good moment to scan other healthcare stocks that might fit your watchlist criteria.

With the shares at $198.84, alongside a 69.57% 1 year total return and an indicated 33.96% intrinsic discount, you have to ask: Is Ligand still underpriced, or is the market already banking on richer future royalties?

Most Popular Narrative: 18.3% Undervalued

With Ligand Pharmaceuticals closing at $198.84 against a narrative fair value estimate of $243.44, many investors are weighing how much of the royalty story is already reflected in the price.

The analysts have a consensus price target of $178.125 for Ligand Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $206.0, and the most bearish reporting a price target of $155.0.

Want to see what sits behind that higher fair value than the analyst target range? The narrative leans heavily on faster earnings growth, richer margins and a punchy future earnings multiple. Curious how those moving parts combine into one 2028 earnings and cash flow picture? The full write up lays out the assumptions step by step.

Result: Fair Value of $243.44 (UNDERVALUED)

However, this hinges on concentrated royalty streams and ongoing deal flow; any pricing pressure or weaker partner execution could quickly challenge that underpriced story.

Another angle on valuation

The royalty narrative points to undervaluation at $243.44, but the P/E picture sends a different signal. At 80.6x earnings, Ligand trades well above the US Pharmaceuticals industry at 20.7x, the peer average at 24x, and a fair ratio of 21.3x. This points to meaningful valuation risk if expectations cool.

Build Your Own Ligand Pharmaceuticals Narrative

If you are not convinced by this view or simply prefer to weigh the inputs yourself, you can build a custom Ligand story in minutes with Do it your way.

A great starting point for your Ligand Pharmaceuticals research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Ligand has caught your attention, do not stop there, broaden your watchlist now so you do not miss other opportunities lining up today.

• Spot potential turnarounds early by scanning these 3532 penny stocks with strong financials that already show stronger financial footing than many expect from low share price names.
• Back long term themes by checking out these 25 AI penny stocks that link artificial intelligence with businesses aiming to grow in this rapidly developing area.
• Zero in on value by reviewing these 868 undervalued stocks based on cash flows that our models flag as trading below what their cash flows might justify.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.